BRKR - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. And welcome to the Bruker Corporation Third Quarter 2021 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please also this event is being recorded. to conference like Minkova. to now would turn over the Miroslava I go Please ahead.

Miroslava Minkova

Good like My I to you, Bruker Investor afternoon. Thank Gary. Development Corporate would Minkova, Director quarter at earnings Relations and Miroslava Bruker’s XXXX to conference is call. name Corporation. Senior of third everyone welcome

Frank Joining Executive Chief and Vice are President CEO; Laukien, on me call and and President Financial our today’s Gerald our Officer. Herman,

referencing Latest release earnings call, addition issued slide today, during PDF the conference this Relations downloaded be on In today’s can we will Investor of earlier we a The Results presentation. be to Bruker’s website. presentation from section the

and During non-GAAP GAAP are financial our today’s website non-GAAP highlighting included to be financial our we call, information. measures Reconciliations release in posted at will on ir.bruker.com. of are earnings our

would I two. slide to like show Safe reference I which Harbor begin, we Before statement, on Bruker’s

you our to of might the of any and and based is X, or the the for future the representing not pandemic, of as and Also Delta and operational XXXX new should this statements During of the well to our as ongoing date other course fourth to or variant, of regarding that Therefore, call, we forward-looking are related as the statements views We spread to conditions financial including available today, materially supply make that rely in current those expected reasons company which will involve events, events filings, COVID-XX The conference quarter on as website February company’s as these differ performance information updated uncertainties, our earnings on today’s to inflationary not subsequent risks our statements chain XX-K the and on statements. intend XXXX. in XXXX. but today. our future SEC’s Form SEC from not our forward-looking differences related such release prior financial outlook risk. as November such by to update those challenges, do note Factors other results forward-looking may and results ongoing discussed outlook the in the our include, following actual information, global that are cause to, of on website. logistics limited release business and

begin with will summary. call Gerald detail. then quarter a more for We the will the today’s financials providing Frank in cover third

would call over turn to CEO, I Now, like the Laukien. Frank Bruker’s to

Frank Laukien

Thank you, Miroslava.

in years earnings and you best As to wish last thank call this Development would Relations the last over Investor five Gerald work Corporate I be may know, us. forward. her her like will Miroslava’s and successful going the her with we for and

good for afternoon, us and call. on everyone, joining you thank earnings today’s Now,

another you EPS improvement delivered see on quarter revenues, with As slide growth. can excellent bookings, and in margin Bruker momentum sustained four,

well to execute is innovate on continued Bruker teams excellent through Our XXXX. managing very in track supply and now well chain well, am publicized financial challenges. I operational to progress that and for confident

in $XXX revenues year-over-year, quarter the included third at XX.X% BEST, Bruker intercompany Bruker’s of net increased basis, million. to the growth organic Instruments On XX.X% XX.X% XX.X% year-over-year For organic increased revenues and which eliminations. Groups Scientific an of XXXX,

of an XX% increase $X.XX reported reported XXX XXXX. in third In tax to On with the Bruker year-over-year it QX non-GAAP tax XX.X%, and third nine uncertain points our continue expanded of operating EPS periods. will discrete performance, the prior to Our gross were On strong XXXX in Accelerate while improvement an excellence quarter of third margin later. XXX on non-GAAP quarter the third $X.XX, diluted of items, to third we up quarter XX.X%, compared step margins XXXX. slide year operating of the the investments. even reached non-GAAP basis, over basis as our In revenue months the of $X.XX bps $X.XX, from XXXX of of and X.X EPS summary, diluted the quarter growth, all quarter of Project for XXXX, in XX.X% included GAAP a dropped and benefit Bruker’s explain favorable which operational quarter Gerald first an performance $X.XX a of through XXXX XXXX third bottomline, five, approximately leverage as to excellent we was show

months revenues of $XX.X basis, and a grew net comprised at by of XX.X% eliminations. increase million of an billion organic XX.X% the first increased by million year-over-year to or revenues XX.X% XXXX. Scientific growth $XXX.X organic Our year-over-year, $X.XXX in BEST, intercompany Instruments On organic in nine

quarter non-GAAP slides the percentage the year-over-year quarter demand three -- comparisons we basis. North saw recovered the Europe, strong region, China, and grew XX% Groups applied where our government, -- third low-XX% in -- Geographically, and by our significantly Project Groups to revenue BioSpin up bookings During in excellent year-to-date margin, Groups businesses. and XXs than to in of our now, XX% for Instruments and and a was our businesses. diagnostics, slower performance quarter segment, science, Group an non-GAAP pandemic semiconductor bookings basis, order Scientific quarter GAAP our of of America turn organic beyond Instruments life business experienced the XXXX. bookings strong a imply. and of stepped from six third industrial gross the more the and seven XXXX performance XXXX and and third third from our trends EPS highlight BEST Asia-Pacific BioSpin and including Scientific $XXX.X Please recovery the was metrology in than million. year-over-year Accelerate Year-to-date, on would accelerated as we growth and to primarily driven XXXX, all what both bookings demand strongly revenue year-over-year, currency in order with Year-to-date, all Scientific Year-to-date, constant operating we and XXXX performance due on academic core third for biopharma, Instruments quarter our order customer more our again

XXXX, revenue year-over-year, NMR strongly NMR, strength for system the saw including demand its systems while revenue of and year-to-date. nine recognition imaging up BioSpin recovered. During preclinical X aftermarket on gigahertz-class was and months BioSpin offerings, activities installation first Systems

During this Netherlands. quarter, the year, system of NMR at in gigahertz the installed its recognition a X.X revenue achieved third BioSpin University third Utrecht gigahertz-class

Press with to week strong consumables, paperwork to Raman Diagnostics Bruker certain the China. the timing demand and continued and was coupled single-cell gigahertz-class a.m. the We and mass instruments growth turn FTIR, in system revenue expect recovery four quarter, has unbiased including International our $XXX.X to as the spectrometry products, from with MALDI-TOF further mass U.S. in delayed $X million, in at revenue continue XD molecular will recognition Bruker fourth NIR, the demand. strong China for CALID BioSpin products conference, our revenue substantially lines. our Heinz, Please fourth Year-to-date, our XXXX of year-over-year, timing research like of product rebounded grew This systems SARS-CoV-X the performance increased timsTOF for quarter, spectroscopy strong MALDI for In products a revenues previously XX science while and testing Molecular into will third other proteomics accelerated and the of execution due host businesses, and IR the Near to in XXXX and from global note next and significant of were in molecular microbiology on XXXX. growth diagnostics we growth We of required that about by tomorrow, revenues of our spec an higher to in ASMS of from revenue the industrial, both healthy Year-to-date benefited receipt Yupo in to Conference in to have proteomics. academic continued revenue saw with tuberculosis expected be quarter Microbiology that Eastern with Biotyper applied strong unbiased innovations and earlier Time revenue PCR Raman proteomics XXXX solutions our year-over-year, Bruker mid-XXs again life declined rebound including while Scientific product driven very line million. spectroscopy platform, revenue well. percentage FTIR for Group

and Turning year-to-date, for and outperforming and the our X-ray, tools businesses advanced Revenues up XXXX September our of included Nano with proteomics Nano’s industrial year-over-year ago strongly on measurement metrology and in to to a relatively third innovation microelectronics contributions well tools the fluorescence Year-to-date, rebounded to Nano Canopy film acquisitions, $XXX.X revenues up single-cell microscopy mid-XXs targeted million. expected Bruker Surfaces bookings Late versus Bruker microelectronics slide a Analysis recovery expectations. grew adding stepped packaging all small very research the continue percentage of and revenue seven strong and Group contribution product Nano CRO and revenue now, science, XXXX, basis portfolio, inspection thickness Biosciences, ongoing X-ray Nano substantially on services. year quarter. strong Nano’s and period. academic industrial with was sharply semicon two the the Nano fourth from acquisition year-to-date in quarter perform metrology tools revenue demand. to advanced closed Life academic with small in backlog. semiconductor tools its

and challenges material projects by BEST year-to-date, demand from BEST, science percentage medtech seen healthy, customers. by slow demand and high-teens superconductor big appears net a due in of logistics. to we and eliminations, inter-company but our chain recovery Turning superconductor grew MRI OEM have contributions driven supply revenue to shortages in BEST the

continue to Accelerate progress Biotyper to highlight make with Moving Project nine our MALDI initiatives. our eight in we with progress good slide X.X slide now, of On the eight, U.S. I and many franchise

you in markets, Biotyper you twice here, as with XXXX, we than European of are lags can Biotypers the in as installed MALDI many and the Europe many aware, than MALDI more the had U.S. penetration June U.S. of as As the our in tell

nearly a we’re customers potential clearance Sepsityper workflow for of with quarter. the the our quarter that have December the late we than adoption third already delighted the training XXX in U.S. U.S. So customers in the end XXX more scheduled FDA XXXX, or obtained at more fourth U.S. have many lot more Since

of recovery kit or year-over-year from recovery. counts our than to end growth course, for and COVID more recovery, and XX% XXXX, sepsis identification with Biotyper the recall, of this relevant in COVID Biotyper than XXXX, helped of it’s Year-to-date, affordable outcomes greater time matters more from for of positive or has culture, third impact than as it like resulted survival. blood microorganisms you Sepsityper every and this but microbiology MALDI of the for just provides including very clinical seems rapid the hour has quarter If when including the MALDI U.S., from again, a order XXX

nine University of Center order award NMR and National Foundation Complex call, a network in establish announced advanced U.S. The Magnetic on three in Medicine, the discussed and NAND, of to gigahertz Madison’s for June a on quarter of National million our this of this University Georgia, Carbohydrate U.S. facility. of academic year, among The institutions, shown second of slide the XXXX NSF As Wisconsin receipt by Science conference Connecticut $XX Recently, School Resonance second the NMR NAND University grant. Research announced we funded X.X or

will ordered and solid University state NMR. NAND at solution of for follows The Wisconsin, Georgia the second NMR. gigahertz order X.X be of system used funded by for NMR for initial was University the state a This Madison

very disease We’re in structural science. biology into in interest by NMR biology, research which growing the set will of in diverse material U.S., scientific a the problems benefit encouraged and gigahertz-class functional

the during progress against months objectives. first of in the strategic and financial and delivered XXXX, excellent summary, So, our Bruker nine third quarter

protect growth strongly and growth buffer our high logistics well. and inventories supply invested in very increased Our Project to a our have we rebounded high successfully and margin challenging initiatives navigate our continue core vendor do Operationally, environment, continue and Accelerate chain where have teams revenue to to P&L. our commitments businesses

as remain. of risks the challenges, For backlog fiscal our logistics manage we the XXXX, well year to positions chain flexibility supply us into year remainder and and high move although,

year year on our also further and for of are raising dual investments excellent Project are in Accelerate year-to-date XXXX. now made am strategy operational very our we and guidance an full our track pleased the excellence. well I X.X for further performance We with we and

call review to Gerald our in performance financial over me and Gerald? detail. turn now our Let will more Herman, outlook who the CFO,

Gerald Herman

third $X.XX $XXX XXXX. and Thank on share, you of revenue in quarter organic XXXX increased EPS XXXX. Bruker’s per review reported highlights, financial XX.X% you, XX.X% quarter of of share, everyone of $X.XX On starting XXXX, to I today. the thank XX. third We increase an joining and approximately in for per non-GAAP Bruker’s in an year-over-year. of revenue us GAAP $X.XX to am EPS quarter million compared the third includes was third of slide year-to-date basis, compared $X.XX the a increase Frank, third quarter which pleased quarter XX%, to XXXX to

third comparison income from in XX.X% began. of somewhat the from a quarter the grew still quarter pandemic XXXX recovery third when operating Our non-GAAP our XXXX softer

XXX in our initiatives Third volume and to quarter driven strong XXXX growth. year-over-year non-GAAP programs. also results operating by These basis continued margin investments our expanded revenue XX.X%, Project excellence points operational include X.X Accelerate and

longer chain Our ultimately in short-term teams handling finished result into operate down as revenue quarter the third of investments payments executed quarter, P&L. term equivalents our increased that delays issues cash, with growth these with far, been make supply the vendor volume, thus to we $XXX approximately logistics commitments inventories We buffer and cash million. slipping and despite shortages with and well protect in But may XXXX. very some well significantly third higher shipments and managed, have

strategic quarter, share inventories, and totaled of program. investments, program new the our substantially acquisitions tax XXXX, no was valid third in the customer X.X of We scale NANO the for two the in for up of There business, shares which approved in of small by CapEx million. of resulting million share cash used was by million the Year-to-date, the investments fund XXXX. In During vendor flow authorization repurchase of income dividend our under our a to quarter payments, in impacted were our and million have May XXXX. third our two-year to flow Group share cash million, repurchases $XX.X until and This in deposits. approximately quarter. timing buildup $XX $XXX Board in repurchases a generated May $X.X cash third free quarter, offset the buffer operating we

nonetheless quarter bridge Our third working XXXX, revenue the XX, revenue of substantially the from gains. of Slide the and improved higher third due ratio efficiency capital-to-revenue quarter shows for XXXX. to

import, organic be of quarter quarter currency of of X.X% XX% to and BioSpin the reflects in quarter due from revenue and paperwork the in systems compared quarter which BioSpin in challenges of the X.X%. were acceleration, revenue XXXX performance paperwork of to fourth in was strong BioSpin’s low businesses. earlier, had foreign net in and related and revenue the estimate high-teens company revenue in positive had was of that eliminations. testing grew system, million previously percent grew also in BEST with increased XXXX range, been any gigahertz XX% increased on approximately quarter forecast the the strength growth class in We above. franchise, Nano’s of in industrial in year-over-year noted China science revenue Nano As recognized low-double a the research a this and primarily continued Overall, revenue a third CALID offset in to XXXX, $XX a range, XX.X%. China, perspective organic revenue by and the of From organic was an revenue. expected from acquisitions contribution range. mouse recognition third revenue, decline academic quarter. recognition Bruker’s life the XXXX, partially the high increased delayed This benefited fourth Biotyper we SARS-CoV-X tailwind which in revenue. NMR performance certain to previously third spectrometry revenue the quarter noted digits QX MALDI

Asia-Pacific by excluding year-over-year, APAC grew third volume off higher revenue organically in high-single a non-GAAP the strong weak prior margin and markets, the of XX% percent Japan. our gross in XX% from BSI of year in slightly on North driven quarter driven XXXX systems third increased revenue grew basis quarter XXXX XXXX, a comparison. an digits. quarter quarter performance revenue and Rest still Third revenue performance BSI quarter low XXXX in P&L basis the Geographically of points XXXX, third in organic low the European our revenue aftermarket by XXX third in And was grew China America of third of and in range, increased non-GAAP QX organically, while shows range to World XX XX.X% other basis. compared the digits mid-single on increased leverage. higher the the quarter Slide XXXX high-teens year-over-year. the XX.X% XXXX.

XXXX, up the of non-GAAP third expense address pandemic temporary were quarter following quarter operating rates, Third that economic normalized in reductions XX.X%, curtailment of XXXX to expenses reflecting the to run XXXX more conditions. we compared cost introduced

Third quarter XXXX certain also step-up expenses X.X operating included investments. Project in the expected Accelerate

the This quarter Our driven XX.X% of in of in and basis third margin was XXX growth, quarter third operating the points XXXX above XXXX. non-GAAP was quarter. by principally volume strong our leverage revenue operating the XX.X%

at in tax tax to For XXXX third resulted shares activity XXXX. rate shares items. discrete XX.X%, XXXX, compensation lower of quarter the million, tax X.X, Weighted XX.X% other from approximate compared estimate over as of effective quarter rate X% discrete in the stock from repurchase third our third quarter, $XXX.X third favorable in our approximately sorry, outstanding quarter significant EPS. year. The of of well of XXXX were the X.X diluted or rate reduction non-GAAP average a as from XXXX in third was activity third quarter resulting benefit the that quarter million share the compensation XXXX, tax our past non-GAAP quarter $X.XX favorability favorable to activity the reflects We stock

our favorable first rose year-over-year quarter XXXX, revenue, driven Finally, topline, XX%, drivers and XX for to of third quarter nine was compared P&L $XXX of tax X.X% XX drivers nine has margins for already to Revenue while the first up first primarily million XXXX. in Slide tailwind, rate Acquisitions or XXXX. third quarter months XXXX. are the XXXX of of the Frank Slide of results operating third third XX.X%, EPS XX.X%. for XXXX gross was the the and growth non-GAAP the the months months in on higher to summarized foreign revenue bridge by nine including similar the improved the with a X.X% covered $X.XX of $X.XX of and added shows exchange organic quarter.

million of free in higher further net the XXXX. cash offset slide chain of address XXXX customer to inventory in first benefited cash million of to we of supply free support $XX.X nine of deposits and the first third shipments timing Year-to-date, quarter approximately and and months risks, XX, generated than months to higher levels Turning and income, nine the from XXXX, flow by higher flow, scale $XX.X higher partially growth the vendor advances. timing

in Our our growth CapEx continued in operational as our excellence capacity spending the reflects initiative. of investments quarter part and productivity

cash XX cycle working of was conversion our of Our XXXX, third days, the at end capital XXXX days third the XXX gradual the of compared improvement to cycle. reduction a in quarter quarter reflecting

now to slide XX. Turning

Given non-GAAP solutions for during and strong expansion once outlook products XXXX quarter, financial the growth, our operating our third our raising and non-GAAP EPS. performance and we’re again margin for revenue demand

XX.X% to for We operating foreign expected revenue to in a to to approximately For XXXX revenue lead fiscal revenue and a to now expected XX.X% now to XX.X% growth points XXX acquisitions basis currency This XXXX. organic XXX growth reported X%. growth Non-GAAP range combined estimate basis of in points XXXX, XXXX to reported expect to XXXX. tailwind we to is year of XX%, to to is of compared compared now XX% for from margin expand XX.X% year-over-year. XX.X%

which approximately to to project level guidance on in to XXXX up year Other now $XXX third for EPS This XX% million, rate this bottomline, represents fiscal represent our EPS After pre-pandemic from to On XXXX. estimated to of experienced would the non-GAAP we XX% an adds of growth compared also non-GAAP the assumptions favorability EPS non-GAAP year in growth XX% XX% $XXX XX% all for listed range slide. XXXX. the the in our million tax are full of XXXX. we quarter, $X.XX non-GAAP

Our currency XXXX. XXXX for September full year XX, foreign ranges of been have as updated rates

mid-single organic growth this quarter digits. For in the revenue implies of the fourth XXXX, outlook

expected which quarter, the be logistics explained as including, quarter quarter the shipments SARS-CoV-X more in to the earlier, XXXX. approximately proteomics factors, quarter with into testing are first, of investments supply when some in and our the X.X with third second to profit all initiatives, or third fourth of quarter million non-GAAP of XXXX result to together and fourth To certain quarters excellent of shift number in biology normalized the key than XXXX, flat of delivered delays, result expect into margin Project meaningful XXXX, the from revenue conclude, China including by and We of push-out second, fourth XXXX were our revenues finally, of improvements These continuing Accelerate margins the impacted a slightly chain may spatial EPS in another quarter headwind and and a compared from BioSpin higher and approximately revenue, in Bruker quarter our $X factors, fourth revenue third, operating down in year-over-year. a EPS.

are products our fiscal We the and our we year raising financial reflecting through demand performance strong market see months for XXXX robust nine significantly, and guidance solutions. the first

XX% organically. Our nine-month by XXXX now approximately year-to-date period comparable exceeds the XXXX pre-pandemic revenue

We with are backlog. enter strong and good well-positioned to momentum XXXX

to start like appreciation you you that, Operator the much. the dedication me. future. advancing begin turn Finally, Miroslava very Miroslava both to Thank to like over now And back like I’d five call to the for Miroslava her best for thank to and years. Relations call with her Q&A Investor the the I’d over session. We Q&A to past over to I’d Gerald the in portion. shaping the insights wish all turn recognizing and program Minkova add the in my Bruker’s and to

reminder, one everyone we you a time and question questions, follow-up. to one As to allow ask yourself in limit for that order

Operator

Instructions] [Operator first from ahead. Puneet SVB with Please Our Leerink. comes question Souda go

Puneet Souda

and question really role. great for next with the the congrats you, wishes Yeah. Hi, quarter, and best for really working on Miroslava, Thanks my Frank. taking

already the trying There’s we to we beat really am reaching So, strong. the a that. to here, obviously, to in quarter is On on quarter the backdrop is is great when just you hand, of But Frank, the were my first a understand. there guide. the organic mid-point, strong that The guidance obviously, what demand we’re see put question range one of So modeling? I had. mid-point versus in,

You year-to-date. bookings highlighted growth more than XX%

MALDI You’re Biotyper strong gigahertz getting placement. is another here.

So walk is flush, budget the if us the coming help you to is supply us components And just chain conservatism, a just chain is could through you on is maybe just the today? question you or worse quarter, side, if softer understand, it the things it from really it mostly could in second a had where get what supply sense wanted highlighted than stand the of here?

Frank Laukien

Yeah. Hi, Puneet.

of year-over-year. big at Obviously, than end up. So the a we’re the the a And up realize our already. from compared -- at, shaping -- thought we just headwind driving we very I very significantly in to give year always in the really and QX for year the mid-point, COVID the already, growth. in very, how think is throughout really coming the full would full took are $XX mean, sort I in and we’re Gerald happy into terrific some so every up that’s margins at guide have of obviously, is and XX% had year managing then growth testing XX% appropriate. looking we seeing right? QX just EPS $X range I more explained million and about guidance We for QX that and what our with XX% step-up organic it improvements million an that category we

the shift, They’re ending no to pervasive. it’s perfect not I question, dramatic And think to but they’re indeed, be think, I a everywhere. to chain supply your year. going that’s just

successfully Our everywhere. I are our very some accepted, gets quoting seeing teams because and how they’re delivery times to very and that’s very, so working that far we’re and hard, have think systems longer it become of customers

orders. So would of even that that is go I or things in all most into come year. QX QX almost later of or mean now next

are and on if rate it’s expected we’re better dramatic our just -- think no we -- metrics hand, was, like, you So the full other than the is QX growth had all I somewhat the and year other changes, terrific. but even

that XXXX, report and then forward in hopefully comment looking entering Obviously, strong rather also QX and continued to next of backlog we sometime we on So we’re with February year. will momentum. flexible when

Puneet Souda

just suppliers, maybe helpful. you give the in customers of us from to push of And what just terms happening terms inflation, of on has your but of just in wanted to update your Bruker to sort significant obviously, of inflationary out sense ability you’re Okay. seeing view a expectations could in a there cost capital since with are, that increases get That’s number potentially and of companies, terms equipment? us that

Frank Laukien

very vendor I is clearly pervasive. we out many inflationary and mean mean, have many Right. contracts, it’s also and long-term areas influence. have areas, I rather pressure in we there very, good relationships significant

of We’re doing pressures the redesign and greater still we’re making than areas decade. are by at course, cost but time in enhance enhancements -- are last there, we significant in many certainly productivity, inflationary any in the

price years. be That’s and at in something in is pricing, pricing will higher Bruker increases other long-term satisfaction. number one are But will customer I our also that also satisfaction, clear. our that this proactively, that looking course, at So priority we’re of say than customer

will to them customers, also that every that’s going for onto cushion gets that by a and loyalty. customer by of price good we try not we’re pass So or but our honored think logistics long-term spike demand some and strategy I long-term to on customer

So in environment to will so seen, other will But we with well and enough to or new this XXXX. obviously, inflationary am on. guidance for I manage when that the in be we -- differently. we’re confident all simply have But am will be more things pressures short-term suggest I manage not that we quite trying that passed spikes pipeline we give

well far XXX more It’s -- bps expansion. so or with has, margin obviously expansion gross it non-operating So margin that far doing in terrific environment. and we’re extremely

Puneet Souda

it. Got

last is me for one Okay. really… And

Frank Laukien

sorry, usually or to I some had one time have so we think two. for Puneet. questions, questions, other am because I think we we I also three need leave

Operator

The America. question from with Bruin Please of is Derik Bank next ahead. De go

Mike Ryskin

or but Hi. about We to for the this the talk called Could And on could of XXXX Thanks about XXXX? I beyond? update NSF the want update to revenues? those in of briefly Derik. Mike taking the past, on to orders an XXXX a how your if This high field the closer this cadence I get start us contributing Ryskin of or is it should when on could level, talked provide you at you about ultra-high be some out. thoughts just deliveries think an to book for and question. want in we order

Frank Laukien

Yeah. Understood.

NSF They’ve our don’t the in one a certainly XXXX ultra-high exact more these have times revenue more five to class or to three not years orders or book or don’t sorry, we’ve I hope into is these now numbers right be NMR quarter. less. down in to I well, -- of year progress fourth to certainly typically in for field order have more, XXXX, system placed and, to years and have years three come made And good in but this one place four delivered no, we in goes that orders, we two expect years. so I XXXX we’ve already, these beyond, So, least It at the NAND quarter. orders. the out. and used years and But target will delivery be XXXX, gigahertz exact

pretty during comment to going and demand, much the up book two period. come not hopefully, on full more but next order the time am is years I for will XXXX So that expectations,

Mike Ryskin

margin at and Okay. on quarter. really if Great. I both strong on operating if supply follow-up wondering Thanks. margin? contribution apart third potentially benefit some the And then quantify or could the affecting imagine about, that. the some you you could and issues of forward, delays that of into talked what you I came I just that that? of the $XX if through nice XXXX, can flow-through, sort a And million a the probably pull gross am parse the in beat, get margin from the sort pretty appreciate profile chain then just I was

Gerald Herman

I Well, that Gerald. will one. take It’s

in group, this line So get operating margin margin volume, case, the performance or very operating It by the and this million industrial of tend in margin good on But the demand of markets particular to revenue the said I’ve gross as event we our true growth $XX in quickly. from driven, markets, applied down performance. semi-metrology strong furthermore, and on markets, research drops different as academic of side, market when our performance see the a only level situation. performance, calls, more not or relative good in a other we’ve to third segments. certainly very It’s bottom that helped we for quarter strong which at perspective biopharma our to good this number industrial, well. revenue That’s seen margin BioSpin

are those the performance So, gross solid margin all line. of pretty margin at carrying

I have we with mention, comment ultimately of you large logistics might We and those So delays, In the on generally value works for either you this units into fall one falls some we into that challenges, next customer items that’s We equipment. particularly need we fact into being pieces it supply not about acceptance reason quarter. ready. high helps really but naturally delayed issues speaking, that is, that just won’t cases, -- the XXXX. a for only facilities chain asked to fall what -- also here. or with specifically might just way have see significantly that, two the or Bruker, be

view of I probably logistics it. some some will level the perspective on we my So high think that’s and see particularly that, delays from with

Frank Laukien

into as account all And the we’ve in guidance… taken

Gerald Herman

Yeah.

Frank Laukien

… course. and guidance for quarter, the for implied fourth full of color year or the the

Mike Ryskin

Thanks and Miroslava. so congrats much Great.

Frank Laukien

Thank you.

Gerald Herman

you. Thank

Operator

Tycho is question from go JPMorgan. Please with next The ahead. Peterson

Rachel Vatnsdal

Hey. Thanks Tycho. This Vatnsdal the is in Rachel for for taking question.

initiatives local can region? to risk your in doesn’t any China, market us on and procurement since players the see you you guys the do manufacture expectations that Bruker also up recent emphasize just through first walk the So seem on in

Frank Laukien

Right. globally are very, and and unique differentiated China. the and very including we are in areas really active, Yeah. most product very often of even mean, we I where in

not it’s in We see something products applications and our by we have locally. So that those I service are for preferences displaced easily and sales mean really support sure and excellent that. China. of we’re aware made that’s

from Chinese very always and Bruker. are products So, very often, our the customers And they’re our with differentiated. very getting just products generally that are the products -- almost are satisfied support

leave political of aware tendencies. primarily. us all will affect at we’re it affect well that I not of They do strongly. but think They I that, not us these do

Rachel Vatnsdal

one then, from And me. Understood. last

as weakness called well. and flagged it call you quarter, a out broad in guys last on So you little Japan this bit some

give region well? demand XQ just you about the and us can for seeing So as outlook in an update trends the you’re

Frank Laukien

that Did you Japan, say was question? the

Gerald Herman

Yeah. Yeah.

Rachel Vatnsdal

Yes. Japan.

Frank Laukien

another have seen there monies think am to bookings quarter. of some expecting I had been. rather supplementary become start weak after I or But sort but has Japan Japan are I NMR extra it are slow hope, special some than after bookings the year, a believe Japan I a the I also Yeah. us after in of there let Olympics. some signs call visibility I had now some don’t budget because think side, Japan, Right and more really into of I’d from the been had seen get and yet, orders there’s have most have any the comment of somewhat available for and better before decent say, aware now -- of -- I been comment. we that they wouldn’t I have fourth quarter data

Rachel Vatnsdal

Great. my Thanks for taking questions.

Frank Laukien

Sure.

Gerald Herman

Sure.

Operator

The question Please Stifel. ahead. Arias next from with is go Dan

Dan Arias

geography the Good to application for on you was that industrial thinking Thanks is a to quarter, the for particular that the afternoon, of Frank, add was focused were bit just or or beyond anything a guys. it comment Board? the where across sort questions. research

Frank Laukien

particularly semiconductor microelectronics tools. the and applied surface spectroscopy It’s broad quite tools other advanced industry. analysis packaging of really in course, X-ray It’s our and or industrial in more serves that surface tools, and even the like molecular businesses or broadly strong,

in investment. scarcities a demand they chip drive are So also and way Bruker, for good because

investment trends factors geopolitical in and by space almost that exception. a area geopolitical industrial just by and also in general, or there’s, likely without of really more But have that is but in why factors independence towards course, to political in demand in strong been very be particular. of driven lot trends, markets Of applied

really very next-generation on for but our lines, line have of not performance product We refresh. products, innovation. productivity also only product on on many we core continued on our work So,

So very very often good we’ve been in -- we found ourselves to a be position. competitive in

in also revenue. our also really done well now businesses quite bookings core in So have and

So it’s broad-based. pretty

Dan Arias

Yeah.

you and we BioSpin, relative it of big Thanks. that the you about the wondering just us finding pandemic comes are how just and think the to color and in lead maybe, on sort when day? items. might through should how I on some time a some lines of things there timing ticket was BioSpin, mean you overall, the that update on fit for of the days the to times where Okay. Maybe could installation just I follow-up have whether earlier

Frank Laukien

good obviously access. a delays And And access Zealand go but country. the done certain a other couldn’t it’s are maybe working couldn’t -- some those Asia-Pacific getting were a to that’s -- some is bigger still Those New and lot better. we’re gotten still countries, question. we -- virtual to a new or but lab better, There and the countries in on or effect. are Australia by in hand, it’s more -- this It’s difficult obviously, in

world revenue, much some America, doing Europe the growth, improving despite And can North deliver, so show ship, where this are but we strong well we’re but remaining In we work and better get methods that and us reasonably that can and to can in dealing there differently. are have -- we’re it now still these parts it’s obviously, new of we allowed shape, situation things an we tools have obviously Western restrictions.

augmented installations been progress customer like some and quite reality that. training much processes. actually So we remarkable virtual it’s how have have improving these we days making. complicated and better We do and It’s via things very really

it’s see the back can results as not guidance. and us from So from you the holding

Dan Arias

Thanks Okay. very much.

Frank Laukien

Sure.

Operator

with is The question Citi. ahead. from Patrick Donnelly Please next go

Unidentified Analyst

for the question. am Patrick that China, Leslie recovery you’re well. is on we’ve I and could but seeing. I as a This you [ph] those wondering talk about taking guys curious about end you markets European Hi. about you. Thank Spire know Donnelly. talked for I Europe my Thank was if little bit

Frank Laukien

strongest Sure. recover was already Europe QX There’s and recover last U.S., already growth now, already of in for year. terms that’s China the the then took certainly QX government spending terms and driver really bookings academic recovered especially U.S. late get of in timing. a while of in right the year than first, going, earlier but bookings. QX in strong to different And began getting began to Europe for it of last to sure. and

so weaker, were and in Europe, Germany bad countries yeah, bookings European that proteomics was little much there there’s to and bit quarter year. third growth of other know some I last the So say. QX in more really because wasn’t some good. revenue last European initiatives but growth a don’t year-over-year, sizable year

Japan now, well, I that So, say and and hope world the to Europe yes, U.S. America, China I hopefully, of you. with third really recover. beginning second, the North first, parts Americas, of helps some only should rest

Unidentified Analyst

Great. you. That Thank helps.

Operator

BTIG. The next Ji Nam Please question is from ahead. go with Sung

Sung Ji Nam

add for Thanks taking your to questions for my Hi. to well all I and as would like Miroslava thanks help.

the what currently Just in the two sorry, ones, Biotyper it, percentage has your install Frank, of but base workflow? MALDI is, I one quick installed Sepsitype if Europe missed adopted

Frank Laukien

I have that I We No. at not… -- think didn’t don’t Right. It number my fingertips. is

Sung Ji Nam

Okay.

Frank Laukien

clinical, about worldwide are all, not the so, one-third multi- are sepsis of Biotyper of clinical, it’s It’s not inherently first right? two-thirds clinical, -- for only Yeah. It’s our non-clinical.

capability reimbursement. environment type but it. U.S. reimbursement Europe, has there So Sepsityper in for they the stronger is much In have the much, been U.S. would in The never low adaptation the

are do U.S., question have it’s So we we specific driver answer seeing bigger number. and think because that. a do I in not I indeed cannot the much I the that in -- not your

Sung Ji Nam

Thank just beyond opportunity? curious such you. Thank testing might where the worry. molecular COVID you diagnostics as of you. growth be about No And seeing then business, Hain, your kind

Frank Laukien

including that array, it’s the of many recovery multiplexing, say, different their PCR resistance patterns. TB, PCR many, would I liquid their a tuberculosis, looks at mostly testing, Well,

coming procedures, there diagnostic it that overshadowed now is clearly and testing. products probably that -- still was recovering were COVID testing, by it but so to while, back a strong that obviously some and continues second have play that For is other to many fiddle play COVID did we like

Japan we’re focusing mostly So, markets. or sell Africa as we on This China. tuberculosis and the you Europe, India testing, not is in Americas in in those something or know, and in

specializations. So it has regional

Sung Ji Nam

so Great. much. Thank you

Operator

ahead. Please Waldman from go Josh Cleveland is Research. question next with The

Josh Waldman

assuming here questions. like laid back something I growth provide incorporate my you I how at year-to-date, be or wonder thinking that below I for And the Gerald, more annual the should could outlook given context in we on order comment think, then analyst up taking next were if about organic comment the X% but heard longer-term overall? orders something XX% Frank, XXXX. year? wondered is growth difficult, on for XXXX. Frank you guess, out meeting, be we the Thanks any if you obviously quarter could I Hey. should to believe XX% comp third growth through I you

Frank Laukien

questions So, lot of here. embedded the Josh, -- a

will the real quick think with BSI… start Gerald I

Gerald Herman

Yeah.

Frank Laukien

year-to-date QX… … or

Gerald Herman

think question… I your

Frank Laukien

right, were right, XX%... very they bookings, around similar, ...order

Gerald Herman

Yeah.

Frank Laukien

Right?

Gerald Herman

order XX% the third year-to-date for over bookings it’s the quarter BSI Groups and full for Actually, growth for months. nine actually

Frank Laukien

And those were organic numbers, right?

Gerald Herman

actually. are very Those Yeah. strong performance. organic It’s bookings

Josh Waldman

quarter the Was trends? year-to-date than stronger third

Frank Laukien

Very similar

Gerald Herman

I’d say. Similar, Yeah.

Frank Laukien

if got I But in recall that quarter in in we gigahertz keep mind in two third NAND. orders in third correctly. came the from quarter, third both the They the quarter, X.X the this

I well, that. mean, read the into trends for wouldn’t step-up. a similar nice So, very yes, you obviously. so I disregard, they’re But and bit three first that anything very was strong very of a if have been But the orders, quarters.

that’s XX% is and the average also three to quarters That year-to-date, quarter… So close quarterly. over close the to very

Gerald Herman

And…

Frank Laukien

… BSI growth.

Gerald Herman

I was add other Josh. going just to thing, one

Josh Waldman

Yeah.

Gerald Herman

It’s each of across all the groups, so those groups…

Josh Waldman

Okay.

Gerald Herman

bookings order on very is well side. the … performing

Frank Laukien

Correct.

Gerald Herman

So group. one that’s It’s important. not simply

not on those am the... cylinders. talking firing about groups the I We’re

Frank Laukien

Groups. Yeah. BSI

Gerald Herman

BSI The Groups

Frank Laukien

trying other some And could we’re repeat -- of please? what I you Josh, were forecast I of the go XXXX, to to not into question, mean, going questions, your But other elements us, your am remind if of sorry, XXXX. some

Josh Waldman

assuming context well… longer step of comps below we the obviously, the automatically should light Yeah. on that, kind something More term guide, significantly, in XXXX be just up of

Frank Laukien

comes year year we this so recovery, level, on recall, not mean, of in And which really right? -- it step aspects, our right? near guidance, with you we said if as this is a many high June, but sort at wonderful. clearly of out strong big only derisking obviously, up XXXX is a And very is just I XXXX, a a targets, we’re our I multiyear mean, in that

we February in have know, you overall and as better outlook picture. quarter we XXXX So guidance and will a report when give the fourth

good very the So really we targets that had XXXX will derisking we in great -- also have momentum. but step-up strong, that given, a

Josh Waldman

Got guys. it. Thanks

Gerald Herman

Sure.

Frank Laukien

you. Thank

Operator

question next Research. Please is ahead. Jack Nephron with go from Meehan The

Jack Meehan

some -- how timsTOF would Good in you in in and/or Thanks. even performance performance afternoon. terms did shipments just of give to color helpful? on quarter, uptake quarter be just wondering overall CALID of broadly, Was timsTOF that the more the could maybe more if is the of how the relative

Frank Laukien

Yeah.

for shipments/revenue So, Jack, quarter third beginning -- some timsTOF to SCP. so already also see exception, have bookings for on the strong no been year the the all was and timsTOF new

which thought addition, proteomic single-cell driver, an to proteomics capability launched essentially it’s have as additional simply because Xst, is technology. the unique for growth really they that June an unbiased additional that on that system In found, $X were needed that budgets system, even special people we quantitative biology were though million they there some

tomorrow we our have of that of three and timsTof very all has quite systems Pro release, and lot we’re press revenue, teaser And -- the So really the will introduced now the been just early more expensive the that will timsTOF shipments. systems. relate morning, we ASMS out I shipping nicely, Pro nice just a the the now quarter, nice quarters, put while orders X that growing third will these by including to two encouraged new

introduced other further And but often customers, significant beneficial also the other We not them and and developed of by a by early original we’re but So workflow software our launching of ASMS key June, being and very timing customers. very June. capability for systems enhancements lot ourselves tomorrow. at

I morning other have then some and think we oriented. have release exciting mass XX we and proteomics more news will for -- that’s o’clock So an tomorrow spec scientifically press

And CCS protein opinion about the many I what would of and key category. to not by it enabled tomorrow, mean advantages only at so collision also I cross-section happy positive We’re will do a identifications new on many key the majority but when not really and leaders, about that also EPS, very There’s examples have we you but take field it’s going and -- early the just a so cell talk the is opinion tomorrow more-and-more to doing just talk leaders, well. very XX that is interest say, it’s or but proteomics new single can proteomics has scale again. that’s and

Jack Meehan

Great.

Looking the idea? pulled to you just these X I fourth Is forward So had third the were generate quarter? the the in you paperwork. in expected sales able were related on Can that forward elaborate it. clarification, to quarter just to also that? $XX million

Frank Laukien

was million The stuff about of the paperwork $XX million. $XX

ended we import that it coming that already million $XX the in It thought $XX certificate. About and go wonderful. paperwork through of into tax million wasn’t would about We’re was up or QX, QX China something was related for NMR into specific not held up that that getting and NMR as get delayed up samples we ended thought very we some qualifier delayed. QX and things calibration need about would then and samples that had they

Bruker NMR I Bruker wouldn’t million to I delayed, so $XX that not business companies. specific, and other is -- anything very specific. the million but was So wouldn’t NMR of very parts it specific. paperwork on say, very But, was other which into or great was that $XX in, NMR should very I China related read came and of

Jack Meehan

it. Got

related that know any things any sorry, fourth should have we about? And follow-up, to just pressure does to your quarter additional one-off guidance

Frank Laukien

then guided in of Europe a a gigahertz, it we’ve in high forecast. look I if Well, contingency our some has don’t plans, but we that. system that, mean, chance or happening, doesn’t, in if X not at gigahertz way have mean, C. we X.X think that a that you B I We worry got that I we covered. even have think, about A, But

nothing pointing wouldn’t some things taking account. good out so. of worth variants occurs major unless December in think -- I -- been new we’ve because But or there’s I at some So something shutdown into

in implied year think shape QX guidance. to our guidance for full and our meet I good we’re

Jack Meehan

you. Thank

Operator

Sachs. The next ahead. question is from go Matt Sykes Please with Goldman

Matt Sykes

that you MALDI taking slide had eight, to just recurring base, there market obstacles grow have that if that to on chart you you my one overall European in. consumables U.S. installed Americas think from what any revenue that for I getting and just base? just Thanks go the and to were prevent do where you back Is a show impact to the revenue Europe. Hi. within wanted would will to it the versus you on your Oh! question I installed me looks squeezing Biotyper leave and base installed what size European stream it to would like question.

Frank Laukien

Okay.

very we’ve So question. -- a good good been

substantial have Americas we well, for think the growth I of in opportunity I the wouldn’t Americas. is say America. first all, -- this that

see you to X,XXX rest is the Canada maybe be The here So XX% Mexico. America would and of Latin XX% U.S. and systems

lot more has slower to Europe, growth there’s for The a -- there’s even the that’s adopt potential sure. been in than So U.S. U.S.

in what’s Europe. consumables the So and the than is in a Two, pretty we assays Biotyper be for actually which part think growth. sustainable of for quite the question, U.S. a is could -- The better MALDI reimbursement implied pull-through your quite bit insightful. U.S.

in systems long-term than on the more average -- pull-through Europe. U.S. I So revenue in

So that be quite with and that’s that for you even would were aiming what question. beneficial maybe

as in APAC. than pull-through than installations, As U.S. we we better in systems in the -- faster consumables Europe MALDI will Biotyper grow even probably in the expect U.S. or an Europe

Matt Sykes

Great. Thank you much, very guys. it. Appreciate

Operator

I would our concludes to back for This the any closing session. to Minkova Miroslava remarks. question-and-answer over turn like conference

Miroslava Minkova

joining for you Thank today. us

XXXX if ASMS us our a you Daylight tomorrow at send please have XX our inbox, yet note Press investor.relations@bruker.com. Conference an If to a.m. Investor you received invite, Eastern at join Scientific wish Time Relations to and not

an Bruker you all forward at Bruker attend a your over Francisco a meeting the been event will with JPMorgan support Bruker the pleasure San It’s during Bruker’s nice Conference During of will or early you also the five in evening. quarter. XXXX the great with past leadership January. you years. directly Healthcare Jefferies participate quarter, fourth for in London the looks to Have Healthcare Thank all. speaking you working Conference. team in

Operator

conference presentation. concluded. now today’s The Thank attending has for you

disconnect. You may now

Bruker (BRKR) 2 Nov 212021 Q3 Earnings call transcript